Optimizing antidepressant management of depression: Current status and future perspectives

Modern Trends in Pharmacopsychiatry

Volumn 27, Issue , 2010, Pages 254-267

  Schwartz, Thomas L ^a   Stahl, Stephen M ^b,c  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 3 [1 [2 [4 BENZOYL 2 (3,4 DIFLUOROPHENYL) 2 MORPHOLINYL]ETHYL] 4 PHENYL 4 PIPERIDINYL] 1,1 DIMETHYLUREA; AMFEBUTAMONE; AMITRIPTYLINE PLUS PERPHENAZINE; ARIPIPRAZOLE; ASENAPINE; BUSPIRONE; DESVENLAFAXINE; EVT 101; FLUOXETINE; GR 159897; LEVO 5 METHYL TETRAHYDROFOLATE; LITHIUM; LURASIDONE; MIRTAZAPINE; MK 0657; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NETAMIFTIDE; NORTRIPTYLINE; OLANZAPINE; PROLYLLEUCYLGLYCINAMIDE; QUETIAPINE; SAR 1022279; SAREDUTANT; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TXT 0300; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN ANTAGONIST; VENLAFAXINE;

ADJUVANT THERAPY; AGITATION; ANHEDONIA; BIPOLAR DEPRESSION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG TOLERABILITY; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; NONHUMAN; PERSONALITY DISORDER; PLACEBO EFFECT; POLYPHARMACY; PRACTICE GUIDELINE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RATING SCALE; REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION;

EID: 78649678444     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000319517     Document Type: Review

References (52)

1. Thase ME: Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 2003;64(Suppl 13):18-25.
2. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH: Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo-and lithium-controlled study. J Affect Disord 2009;112:36-49.
3. *D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-459.
4. Schwartz TL, Thase M, Stormon L: Treatment outcomes with acute pharmacotherapy/psychotherapy; in Schwartz T, Petersen T (eds): Depression: Treatment Strategies and Management, ed 1. New York, Taylor and Francis, 2006.
5. Szegedi A, Jansen WT, van Willigenburg A P, van der Meulen E, Stassen HH, Thase ME: Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6, 562 patients. J Clin Psychiatry 2009;70:344-353.
6. *D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
7. Stahl SM: Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Approaches, ed 3. Cambridge, Cambridge University Press, 2008.
8. Zajecka JM, Goldstein C: Combining medication to achieve remission; in Schwartz T, Petersen T (eds): Depression: Treatment Strategies and Management, ed 2. New York, Informa, 2009.
9. Schwartz TL, Rashid A: Augmentation and combination pharmacotherapy trends in major depressive disorder: results of a brief survey of psychiatrists. Pharm Ther 2007;32:28-31.
10. Stahl SM: The 7 habits of highly effective psychopharmacologists. Part 1. J Clin Psychiatry 2000;61:242-243.
11. Walsh BT, Seidman SN, Sysko R, Gould M: Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-1847.
12. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, revised. Washington, American Psychiatric Publishing, 2000.
13. Gregory RJ, Chlebowski S, Kang D, Remen AL, Soderberg MG, Stepkovitch J, Virk S: A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychother Theory Res Pract Training 2008;45:28-41.
14. Lynch TR, Trost WT, Salsman N, Linehan MM: Dialectical behavior therapy for borderline personality disorder. Annu Rev Clin Psychol 2007;3:181-205.
15. Greenberg RP: Essential ingredients for successful psychotherapy: effect of common factors; in Dewan M, Steenbarger B, Greenberg S (eds): The Art and Science of Brief Psychotherapies - A Practitioner's Guide. Washington, American Psychiatric Publishing, 2004.
16. Zimmerman M, McGlinchey JB, Chelminski I: Measurement-based care and outcome measures: implications for practice; in Schwartz T, Petersen T (eds): Treatment Strategies and Management, ed 2. New York, Informa, 2009.
17. Stahl SM: Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression. J Clin Psychiatry 2010;71:93.
18. Stahl SM: Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr 2010;15:79-94.
19. Stahl SM: Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009;14:536-546.
20. Nichols AI, Fatato P, Shenouda M, Paul J, Isler JA, Pedersen RD, Jiang Q, Ahmed S, Patroneva A: The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2009;49:219-228.
21. Stahl SM: Stahl's Essential Psychopharmacology, ed 3. Cambridge, Cambridge University Press, 2008.
22. Wise DD, Felker A, Stahl SM: Tailoring treatment of depression for women across the reproductive life cycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology. CNS Spectr 2008;13:647-662.
23. Stahl SM: Essential Psychopharmacology. The Prescriber's Guide. Cambridge, Cambridge University Press, 2005.
24. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H, Moonstone Study Group: Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009;14:299-313.
25. Winter HR, Earley WR, Hamer-Maansson JE, Davis PC, Smith MA: Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008;18:81-98.
26. Deeks ED, Keating GM: Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. Drugs 2008;68:1115-1137.
27. Papakostas GI, Shelton RC, Smith J, Fava M: Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry; 68:826-831.
28. Stahl SM: Do dopamine partial agonists have partial efficacy as antipsychotics? CNS Spectr 2008;13:279-282.
29. Lehto SM, Kuikka J, Tolmunen T, Hintikka J, Viinamaki H, Vanninen R, Haatainen K, Koivumaa-Honkanen H, Honkalampi K, Tiihonen J: Temporal cortex dopamine D2/3 receptor binding in major depression. Psychiatry Clin Neurosci 2008;62:345-348.
30. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A: Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 2008;22:1480-1486.
31. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A: Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:829-836.
32. http://ww w.fr x.com/ne ws/PressRelease.aspx?ID=1347817 (accessed July 21, 2010).
33. Stahl SM, Fava M, Trivedi M, Caputo A, Shah A, Post A: Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71:616-626.
34. Stahl SM: Novel therapeutics for depression: l-methylfolate as a trimonoamine modulator and antidepressant augmenting agent. CNS Spectr 2007;12:423-428.
35. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Francon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G: Stimulation of the beta3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 2008;33:574-587.
36. Stahl SM, Wise DD: The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders. CNS Spectr 2008;13:467-483.
37. Ehrensing RH, Kastin AJ, Wurzlow GF, Michell GF, Mebane AH: Improvement in major depression after low subcutaneous doses of MIF-1. J Affect Disord 1994;31:227-233.
38. Overstreet DH, Hlavka J, Feighner J P, Nicolau G, Freed JS: Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression. Psychopharmacology 2004;175:303-309.
39. Montgomery SA, Feighner J P, Sverdlov L, Shrivastava RK, Cunningham LA, Kiev A, Hlavka J, Tonelli G: Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder. Int J Neuropsychopharmacol 2006;9:517-528.
40. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, et al: Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001;299:449-458.
41. Nowak G, Ordway GA, Paul IA: Alteration in the N-methyl-d-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995;675:157-164.
42. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63856-864.
43. White JM, Ryan CF: Pharmacological properties of ketamine. Drug Alcohol Rev 1996;15145-155.
44. Anonymous: NR2B antagonist pursued for treatment resistant depression. Nat Rev Drug Discov 2009;8:349.
45. Manabe T: Molecular mechanisms for memory formation. Brain Nerve 2008;60:707-715.
46. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S: Binding properties of SA4503, a novel and selective s1 receptor agonist. Eur J Pharmacol 1996;306:271-279.
47. Bergeron R, Debonnel G: Effects of low and high doses of selective sigma ligands: further evidence suggesting the existence of different subtypes of sigma receptors. Psychopharmacology 1997;129:215-224.
48. Stahl SM: The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 2008;69:1673-1674.
49. Hayashi T, Stahl SM: Sigma 1 receptors and its role in the treatment of mood disorders. Drugs Future 2009;34:137-146.
50. Avery DH, Holtzheimer PE III, Fawaz W, Russo J, Neumaier J, Dunner DL, Haynor DR, Claypoole KH, Wajdik C, Roy-Byrne P: A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006;59:187-194.
51. Mayberg HS, Lozano AM, Von V, McNeely HE, Seminowicz D, Hamani C, Schwab JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression. Neuron 2005;45:651-660.
52. Dougherty DD, Thase ME, Howland RH, Evans KC, Harsch H, Kondziolka D, et al: Feasibility study of an implantable cortical stimulation system for patients with major depressive disorder. Presented at the Society of Biological Psychiatry 63rd Annual Meeting, Washington, 2008.